BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 2, Issue 2
  • This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Nephrology
ISSN
2220-6124
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial
©2013 Baishideng Publishing Group Co.
World J Nephrol. May 6, 2013; 2(2): 17-25
Published online May 6, 2013. doi: 10.5527/wjn.v2.i2.17
Table 4 Urate lowering drugs
Pharmacologic options for the treatment of hyperuricemia
Xanthine-oxidase inhibitors: Allopurinol, febuxostat
Uricosuric agents: Probenecid, sulfinpyrazone, benzbromarone
Uricase: Rasburicase, pegloticase
Drugs and contrast media with hypouricemic properties, not primarily intended for the treatment of hyperuricemia
Acetohexamide, azauridine, chlorprothixene, dicumarol, estrogens, fenofibrate, glyceryl guaiacolate, iopanoic acid, losartan,meglumine iodapamide, phenylbutazone, salicylates and other NSAIDs, sodium diatrizoate, trimetoprim-sulfamethoxazole
NSAIDs: Nonsteroidal anti-inflammatory drugs.
Full Size Table
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.